Blog: Research

Targeting Blood-clotting Protein Can Restore Brain’s Potential to Repair Myelin Layer, Study Shows

8 November 2017

Source Multiple Sclerosis News Today:

A blood-clotting protein called fibrinogen prevents myelin production and blocks the neuron remyelination repair process in mice, a study finds.

Cladribine: new oral treatment to be available for people with relapsing MS

8 November 2017

Source MS Society:

A new oral treatment for relapsing MS, called cladribine, will be made available on the NHS in England and Wales within the next three months.

Diagnostic Blood Test May Be Able to Distinguish Between RRMS and PPMS, Researchers Say

8 November 2017

Source Mutiple Sclerosis News Today:

In the future, a blood test may make diagnosing multiple sclerosis (MS) much easier, thanks to newly identified biomarker patterns that distinguish between MS patients and healthy people.

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

31 October 2017

Source Labiotech.eu

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research.

Positive results for clinical trial in progressive MS

31 October 2017

Source MS Society:

Researchers in the US have proclaimed their initial test of ibudilast for MS a success.

MS Society Research Talk 13th November

31 October 2017

Research Talk

Date: Monday 13th November 2017, Time: 10:30 - 13:30 Venue: The Salvation Army Hall Chalfont Close, Lower Earley, RG6 5HZ

3D printing brain scans helps doctors with a tricky diagnosis

5 October 2017

Source Tech Crunch:

When there’s a problem in the brain, it pays to be precise — every millimeter counts with something like a tumor or blocked artery.

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

4 October 2017

Source Multiple Sclerosis News Today:

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease.

Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions....

Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration

22 September 2017

Source Multiple Sclerosis News Today:

Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.

New study to look at impact of early treatment with aggressive DMTs

22 September 2017

Source MS Society:

A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.

Pages

Category

Archive